Perspectives of Cosmesis following Breast Conservation for Multifocal and Multicentric Breast Cancers
Table 1
Summary of demographic, clinicopathologic, and outcome data for study population.
Clinicopathologic characteristic
MFMCBC ()
Multifocal (MF)
Multicentric (MC)
value
(%)
(%)
(%)
Age in years
Median (range)
45.5 (28–67)
45.5 (31–67)
45.0 (28–52)
0.26
Mean (SD)
46.08 (9.6)
47.5 (11.2)
43.9 (6.2)
0.26
Ethnicity
Chinese
28
(70.0)
19
(67.9)
9
(32.1)
0.20
Other Asian
11
(27.5)
5
(45.5)
6
(54.5)
Caucasian
1
(2.5)
0
1
(100)
Mode of presentation
Symptomatic tumours
29
(72.5)
18
(62.1)
11
(37.9)
0.67
Screen detected lesions
11
(27.5)
5
(45.5)
6
(54.5)
Pathologic tumour size in mm
Median (range)
20.0
18.5 (0–72)
20.0 (0–55)
Mean (SD)
19.6 (14)
20.0 (14.9)
20.1 (12.22)
0.99
<20 mm (T1)
23
(57.5)
14
(60.9)
9
(39.1)
0.85
20–<50 mm (T2)
14
(35.0)
8
(57.1)
6
(42.9)
>50 mm (T3)
2
(5.0)
1
(50.0)
1
(50.0)
Skin and/or chest wall involved (T4)
1
(2.5)
0
1
(100)
Stage at diagnosis
0
5
(12.5)
4
(80.0)
1
(20.0)
0.06
I
13
(32.5)
9
(69.2)
4
(30.8)
II
17
(42.5)
7
(41.2)
10
(58.8)
III
5
(12.5)
4
(80.0)
1
(20.0)
IV
0
Histological type
DCIS
5
(12.5)
4
(80.0)
1
(20.0)
0.21
Invasive ductal
30
(75.0)
19
(63.3)
11
(36.7)
Invasive lobular
4
(10.0)
1
(25.0)
3
(75.0)
Other invasive
1
(2.5)
0
1
(100)
Grade
DCIS
5
(12.5)
4
(80.0)
1
(20.0)
0.02
1
6
(15.0)
3
(50.0)
3
(50.0)
2
13
(32.5)
4
(30.8)
9
(69.2)
3
15
(37.5)
13
(86.7)
2
(13.3)
Unknown
1
(2.5)
1
(100)
Hormone-receptor status
Positive
28
(70.0)
15
(53.6)
13
(46.4)
0.51
Negative
10
(25.0)
7
(70.0)
3
(30.0)
Unknown
2
(5.0)
2
(100)
0
Neoadjuvant medical therapy
No
11
(27.5)
5
(45.5)
6
(54.5)
0.25
Yes
29
(72.5)
19
(65.5)
10
(34.5)
Surgical procedure
BCT
34
(85.0)
21
(87.5
13
(81.3
0.46
Mastectomy by need
5
(12.5)
2
(8.3)
3
(18.7)
Mastectomy by choice
1
(2.5)
1
(4.2)
Reoperations
4
(10.0)
Axillary dissection
1
(2.5)
1
Missed multicentric
3
(7.5)
3
Recurrence
Locoregional recurrence
1
(2.5)
1
Distant disease/death
2
(5.0)
1
1
Median follow-up (months)
59
(range)
(43–75)
5-year breast cancer-specific survival
95.7%
100%
87.5%
Log-rank test: 0.47
5-year disease-free survival
92.7%
100%
80.8%
Log-rank test: 0.52
MFMCBC: multifocal, multicentric breast cancer. BCT: breast conservation treatment; SD: standard deviation. Dimension of largest lesion. +Percentage expressed as the number undergoing BCT in the MF or MC group, respectively.
